• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Valneva SE

    6/26/25 7:30:42 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VALN alert in real time by email
    6-K 1 a6-kcoverpagetemplate.htm 6-K Document



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
    SECURITIES EXCHANGE ACT OF 1934

    Date of Report: June 26, 2025

    Commission File Number: 001-40377

    Valneva SE
    (Translation of registrant's name into English)

    6 rue Alain Bombard
    44800 Saint-Herblain, France
    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.


    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.



    On June 26, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in this Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the registrant's Registration Statement on Form F-3 (File No. 333-286071).

    Exhibit
    Exhibit 99.1
    Press release dated June 26, 2025











    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    Valneva SE (Registrant)
    Date: June 26, 2025
    /s/ Thomas Lingelbach
    Thomas Lingelbach
    Chief Executive Officer and President



    Get the next $VALN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VALN

    DatePrice TargetRatingAnalyst
    8/19/2025$18.00Buy
    H.C. Wainwright
    8/3/2022$34.00Buy
    H.C. Wainwright
    More analyst ratings

    $VALN
    Financials

    Live finance-specific insights

    View All

    Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

    Total revenues of €97.6 million compared to €70.8 million in the first half of 2024Cash and cash equivalents of €161.3 million at end of June 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), August 12, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year, ended June 30, 2025, and confirmed its 2025 financial guidance. The half year financial report, including the condensed consolidated interim financial report and the half year management report, is available on the Company's website (Financial Reports – Valneva). Valneva will

    8/12/25 1:00:00 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

    Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva). Valneva will provide a live webcast of its first quarter 2025 results conference call begi

    5/7/25 1:00:00 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

    Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private placement and 67% reduction in operating cash burnSubstantial clinical and regulatory progress in 2024; further data readouts, product approvals and label extensions anticipated in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), March 20, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its consolidated financial results for the y

    3/20/25 2:00:00 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VALN
    Leadership Updates

    Live Leadership Updates

    View All

    Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

    Saint-Herblain, France, June 26, 2025 – Valneva SE, (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world's largest influenza vaccine companies, for the marketing and distribution of Valneva's three proprietary vaccines in Germany. Under the agreed terms, CSL Seqirus will start commercializing Valneva's single-dose chikungunya vaccine IXCHIQ® from July 2025, and Valneva's Japanese Encephalitis vaccine IXIARO® and cholera/ETEC1 vaccine DUKORAL® from January 2026. This new agreement with CSL Seqirus replaces the marketing and distribution agreement Valneva signed with Bavarian Nordic in 20212, which is due to conclude

    6/26/25 1:00:00 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

    Saint-Herblain (France), June 25, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Annual General Meeting held today in Lyon, France. Among the adopted resolutions were the approval of the 2024 financial statements, delegations for the Board of Directors to increase Valneva's share capital and/or issue financial instruments, the appointment of Dr. Gerd Zettlmeissl to the Board for a three-year term and the reappointment of Mr. James Sulat for a one-year term. Dr. Gerd Zettlmeissl is a vaccine expert and Biotech Entrepreneur with more than 30 years

    6/25/25 11:45:00 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

    Saint-Herblain (France), June 26, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2023 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, and the appointment of a new director to its Board. Ms. Danièle Guyot-Caparros was appointed to Valneva's Board of Directors for a three-year term. Ms. Guyot-Caparros has a proven track record in finance and business

    6/26/24 11:45:00 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VALN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

    Saint Herblain (France), August 18, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252. In addition to the adolescent data, Health Canada's label extension application included IXCHIQ®'s antibody persistence data, which show that the vaccine's immune response was sustained for 24 months by 97% of

    8/18/25 1:00:00 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

    Total revenues of €97.6 million compared to €70.8 million in the first half of 2024Cash and cash equivalents of €161.3 million at end of June 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), August 12, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year, ended June 30, 2025, and confirmed its 2025 financial guidance. The half year financial report, including the condensed consolidated interim financial report and the half year management report, is available on the Company's website (Financial Reports – Valneva). Valneva will

    8/12/25 1:00:00 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

    Saint Herblain (France), August 7, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV. The FDA decision follows the announcement in July by the European Medicines Agency (EMA)1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a

    8/7/25 1:17:48 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VALN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Valneva SE with a new price target

    H.C. Wainwright resumed coverage of Valneva SE with a rating of Buy and set a new price target of $18.00

    8/19/25 8:36:26 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Valneva SE with a new price target

    H.C. Wainwright initiated coverage of Valneva SE with a rating of Buy and set a new price target of $34.00

    8/3/22 7:27:56 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VALN
    SEC Filings

    View All

    SEC Form 6-K filed by Valneva SE

    6-K - Valneva SE (0001836564) (Filer)

    8/18/25 9:45:21 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Valneva SE

    6-K - Valneva SE (0001836564) (Filer)

    8/12/25 9:44:38 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Valneva SE

    6-K - Valneva SE (0001836564) (Filer)

    8/7/25 8:26:13 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VALN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Valneva SE

    SC 13D/A - Valneva SE (0001836564) (Subject)

    9/20/24 4:00:37 PM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Valneva SE (Amendment)

    SC 13G/A - Valneva SE (0001836564) (Subject)

    2/14/24 8:59:33 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Valneva SE (Amendment)

    SC 13D/A - Valneva SE (0001836564) (Subject)

    6/30/23 9:00:06 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care